Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) have earned a consensus recommendation of “Buy” from the sixteen brokerages that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $69.50.

A number of equities analysts have recently commented on AERI shares. Canaccord Genuity set a $65.00 price objective on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 16th. JMP Securities set a $68.00 price objective on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Cantor Fitzgerald reissued a “buy” rating and set a $62.00 price objective on shares of Aerie Pharmaceuticals in a research report on Wednesday, October 11th. Cowen reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Thursday, October 5th. Finally, Mizuho reissued a “buy” rating and set a $70.00 price objective on shares of Aerie Pharmaceuticals in a research report on Monday, October 2nd.

Shares of Aerie Pharmaceuticals (NASDAQ AERI) traded up $0.65 during trading on Monday, hitting $64.90. The stock had a trading volume of 394,472 shares, compared to its average volume of 295,309. Aerie Pharmaceuticals has a 1-year low of $35.50 and a 1-year high of $66.25. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24.

Hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. lifted its stake in Aerie Pharmaceuticals by 11.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after purchasing an additional 275 shares during the last quarter. Quantbot Technologies LP lifted its stake in Aerie Pharmaceuticals by 792.5% during the third quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock worth $144,000 after purchasing an additional 2,647 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in Aerie Pharmaceuticals by 2,711.4% during the second quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after purchasing an additional 3,579 shares during the last quarter. Amalgamated Bank purchased a new stake in Aerie Pharmaceuticals during the second quarter worth approximately $204,000. Finally, Palisade Capital Management LLC NJ purchased a new stake in Aerie Pharmaceuticals during the second quarter worth approximately $212,000.

WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/12/02/aerie-pharmaceuticals-inc-aeri-receives-consensus-rating-of-buy-from-analysts.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.